MDCG 2025: The New Era of Vigilance & Trend Reporting for Medical Devices

Introduction

The European regulatory landscape is evolving once again. With the upcoming MDCG 2025 guidance, medical device manufacturers face a major shift in how post-market vigilance is managed. Trend reporting — once seen as optional or secondary — is now a mandatory requirement.

This change will fundamentally reshape how manufacturers track, analyse, and report device performance in the field. More importantly, it reinforces Europe’s commitment to proactive patient safety.

---

What’s Changing?

Under MDCG 2025, manufacturers must detect and report:

• Non-serious incidents

• Expected side effects

• Erroneous results

But here’s the new twist: reporting is required when these events show statistically significant increases compared to historical or expected performance.

In other words, regulators now expect companies to:

✔ Establish clear statistical thresholds

✔ Track device performance globally in near real time

✔ Demonstrate integration of PMS (Post-Market Surveillance) with QMS (Quality Management System)

✔ Maintain ready-to-submit reports aligned with EUDAMED vigilance requirements

---

Why It Matters

This isn’t just another paperwork exercise. Trend reporting acts as an early-warning system:

• It highlights subtle but important shifts in safety profiles.

• It empowers manufacturers to detect issues before they escalate into recalls or FSCA actions.

• It reassures regulators that the manufacturer has tight control over post-market risk management.

Failing to comply won’t just slow down your audits—it could put your CE marking and market access at risk.

---

How to Stay Ahead: Technology + Expertise

Manual vigilance tracking simply won’t cut it under MDCG 2025. At Bioexcel, we’ve combined regulatory expertise with VigiX — our AI-powered materiovigilance platform — to help manufacturers meet these new demands with ease.

Here’s how VigiX supports you:

👉 Automated Trend Detection – real-time algorithms to spot statistically significant shifts

👉 Global Data Integration – combines complaints, literature, registries, and feedback into a unified dashboard

👉 MTR-Ready Reports for EUDAMED – structured outputs aligned with EU vigilance formats

👉 Regulator-Ready Documentation – seamless integration with PMS + QMS records

The result: faster reporting, reduced compliance burden, and stronger regulator confidence.

---

What It Means for Manufacturers

• Proactive Compliance: You don’t wait for issues to pile up; you detect and address them early.

• Operational Efficiency: Automated systems replace manual spreadsheets and fragmented tracking.

• Regulatory Confidence: Demonstrating trend reporting competence strengthens your CE submissions and audits.

• Patient Safety: Ultimately, this shift prioritises patients — and companies that adapt quickly will earn trust and reputation benefits.

---

The Bottom Line

MDCG 2025 is not just a regulatory update — it’s a paradigm shift in vigilance. Manufacturers must embrace trend reporting as a core part of their post-market strategy, not a box-ticking exercise.

With the right tools and processes in place, this doesn’t have to be a burden. Instead, it can become a competitive advantage — proving to regulators, partners, and patients that your organisation prioritises safety, compliance, and innovation.

At Bioexcel, we’re ready to guide you through this transition with VigiX materiovigilance automation.

💡Want to see how VigiX can simplify your MDCG 2025 compliance?